 |
|
|
| |
Safety and Efficacy of Glecaprevir/Pibrentasvir in Patients Aged 65 Years or Older With Chronic Hepatitis C:
A Pooled Analysis of Phase 2 and 3 Clinical Trials
|
| |
| |
Reported by Jules Levin
AASLD - The Liver Meeti ng of the American Associati on for the Study of Liver Diseases (AASLD), October 20-24, 2017, Washington, District of Columbia, United States
Graham R Foster1, Sarah Kopecky-Bromberg2, Yang Lei2, Roger Trinh2, Federico Mensa2
1Hepatology Unit, Queen Mary University of London, London, United Kingdom; 2AbbVie Inc., North Chicago, Illinois, United States
|
| |
|
|
|
|
|
